CEO David Fischel described 2025 as a year of “tremendous progress,” emphasizing technological and commercial advancements despite ongoing challenges. Fischel highlighted the company’s mission to ...

ST. LOUIS, March 09, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial ...

Pulse Biosciences (Nasdaq:PLSE) today announced clinical findings demonstrating the durability of its nPulse Vybrance system.

Imricor belongs to a rare class of medtech company we call category creators — businesses that invent an entirely new treatment modality, hold a monopoly position from day one, and face no direct ...

When dentist Dr Loo Yie Jin was told that his pancreatic cancer had spread to his liver, the news was devastating. He had already undergone surgery and ...

The company aims to scale Magic catheter manufacturing to 500 units per month by year-end while expanding GenesisX installations.

Stereotaxis (NYSE:STXS) today reported its fourth-quarter and full-year financial results ahead of expected growth in 2026.